Selumetinib for adjuvant treatment of patients with stage III or IV differentiated thyroid cancer
The FDA ( Food and Drug Administration ) has granted Orphan Drug Designation for the investigational MEK 1/2 inhibitor, Selumetinib for adjuvant treatment of patients with stage III or IV differentiat ...
read article